Infringement Analysis in Strasbourg.

A patent infringement analysis Strasbourg rights-holders can rely on must be built for the way France actually proves infringement — through an ex parte court-ordered seizure, a single nationally exclusive court in Paris, and, for European patents, a pan-European route running in parallel. Strasbourg is the capital of the Grand Est region and the French anchor of the trinational Upper Rhine “BioValley” cluster it shares with Basel and Freiburg, a life-sciences and fine-chemicals corridor sitting directly on the German border. Yet no patent case is tried in Strasbourg itself: France reserves all patent infringement and validity litigation to the Paris Judicial Court, with appeals to the Paris Court of Appeal. That centralisation, combined with France’s powerful saisie-contrefaçon and its founding role in the Unified Patent Court, gives a Strasbourg portfolio owner a distinctive set of levers. PerspireIP builds the element-by-element claim charts and dated evidence-of-use that a Paris judge, a UPC panel and a seizing expert can adopt.

Where a patent infringement analysis Strasbourg case is actually heard

France does not spread patent cases across its regional courts. Since a long-standing centralisation reform, patent infringement and nullity actions are heard exclusively by the Paris Judicial Court (tribunal judiciaire de Paris), whose specialised third chamber holds sole national jurisdiction over patents — whether the right in issue is a French national patent or the French part of a European patent. A Strasbourg-based pharmaceutical maker, chemical producer or biotech company therefore litigates its patents in Paris, not in the Alsace courts. Appeals run to the Paris Court of Appeal (cour d’appel de Paris), so both instances sit before the same specialised bench.

Two features of that forum shape how the analysis must be written. Cases on the merits are decided by a panel of three specialist judges, while preliminary injunctions and ex parte seizure orders are handled by a single judge who must be persuaded quickly and on paper. Since April 2020 the court also shares validity jurisdiction with INPI, the French patent office, which now hears administrative revocation and opposition actions against French patents. For a Strasbourg claimant the practical consequence is clear: the entire evidentiary file has to be built for a Paris courtroom and a French-speaking specialist bench, long before any local hearing is imagined.

• Paris Judicial Court — the single court with exclusive national jurisdiction over French patent infringement and validity actions, sitting in a dedicated IP chamber
• Paris Court of Appeal — reviews first-instance patent judgments; the same specialised forum on appeal
• INPI validity track — since April 2020 the French patent office shares jurisdiction over patent validity through administrative revocation and opposition
• No Strasbourg forum — despite Alsace’s industrial weight, no patent case is tried in the city itself; the analysis must be built for Paris

The saisie-contrefaçon: how France proves infringement

The single feature that makes French patent proof distinctive is the saisie-contrefaçon — an infringement seizure that is the backbone of French infringement evidence and one of the most powerful pre-trial tools in Europe. Because France has no US-style discovery, roughly four in five French patent actions open with a saisie. On an ex parte application to the president of the competent court, a rights-holder obtains an order authorising a commissaire de justice (the reformed office that replaced the former huissier/bailiff) — usually accompanied by an independent patent expert — to enter the alleged infringer’s premises without warning, describe the accused product and process, seize samples, and take copies of manufacturing and commercial records.

The seizure produces a formal report that becomes the factual foundation of the case, so the infringement read behind it has to anticipate what the operation will bring back. Two French details drive the drafting. First, the order and the seizure must be tightly scoped: an over-broad or poorly justified saisie can be annulled, and with it the evidence. Second, the substantive infringement suit must be filed within a short statutory window after the seizure or the measure lapses. A useful analysis therefore does more than reach a conclusion — it maps each claim limitation to the specific documents, samples and process parameters a commissaire de justice should be sent to capture.

• Saisie-contrefaçon — an ex parte infringement seizure that documents the accused product and process before trial, in the absence of discovery; some 80% of French patent actions begin with one
• Commissaire de justice — the judicial officer (formerly the huissier) who carries out the seizure, typically alongside an independent technical expert
• Tightly scoped order — the seizure must stay within the terms of the authorising order; over-reach risks annulment of the evidence
• Short filing deadline — the merits action must follow the seizure within the statutory period or the saisie lapses

This is why a patent infringement analysis Strasbourg parties commission cannot stop at a tidy opinion. It must justify the seizure to a single judge, direct what the commissaire de justice looks for, and be written so the seized material slots straight into mapped claim limitations.

France, the UPC and the Paris central division

France is a founding member of the Unified Patent Court (UPC), live since 1 June 2023, and Paris hosts the seat of the UPC Central Division. So for a European patent that has not been opted out, a second, pan-European route runs alongside the national French one. A UPC judgment reaches across every participating member state at once, which changes the calculus for a Strasbourg patentee weighing a purely French action in Paris against a continent-wide injunction covering the single market its exports serve.

The allocation of subject matter matters for an Alsace docket. The Paris seat of the central division handles, among others, physics (IPC G) and electricity (IPC H), together with performing-operations/transport, textiles and fixed-construction cases; the Milan section took over much of the former London competence for human-necessities, pharma and chemistry, while Munich handles mechanical engineering. The strategic fork is the opt-out: during the transitional period a proprietor can remove a classic European patent from the UPC’s reach, keeping enforcement before the Paris Judicial Court alone, or leave it in play to unlock the pan-European route while exposing it to a single central revocation. Whether to opt out, and which forum to enforce in, is a decision the infringement analysis has to inform.

• National route — the Paris Judicial Court for French patents and validated European patents kept out of the UPC
• UPC route — infringement and revocation of non-opted-out European patents and unitary patents, with pan-European effect; the Central Division’s seat is in Paris, with sections in Milan and Munich
• Subject-matter split — Paris hears physics and electricity cases; Milan carries much of the pharma and chemistry work; Munich takes mechanical engineering
• Opt-out choice — keeping a European patent in or out of the UPC shapes the forum, the reach of any injunction and the exposure to central revocation

Cross-border enforcement on the Upper Rhine

Strasbourg’s defining commercial fact is that it sits on the Rhine, minutes from Germany. The city is the French pillar of BioValley, Europe’s only trinational life-sciences cluster, founded in 1996 to link Alsace, the German state of Baden-Württemberg and the Basel region of Switzerland. For a patent owner that means an accused product made or sold in Strasbourg is very often made or sold across the border in Germany too — and enforcement strategy has to account for both jurisdictions at once.

That cross-border reality cuts two ways. Before the UPC, a rights-holder would run parallel national actions — a French saisie-contrefaçon plus a German infringement suit before a court such as Mannheim or Düsseldorf, each with its own evidence rules. With the UPC, a single non-opted-out European patent can now be enforced against activity on both banks of the Rhine in one proceeding with pan-European effect. The infringement analysis is the same underlying document either way, but it must be built to satisfy the toughest evidentiary standard in play — French saisie scoping, German-style technical rigour, or the UPC’s technically qualified panels — so the file travels across the Rhine without being rebuilt.

• BioValley corridor — Strasbourg anchors the France-Germany-Switzerland Upper Rhine life-sciences cluster, so infringing activity commonly spans the border
• Parallel national actions — a French saisie can be coordinated with a German infringement suit when a European patent is opted out or purely national rights are in play
• Single UPC action — a non-opted-out European or unitary patent can be enforced against activity on both banks of the Rhine in one pan-European proceeding
• Portable evidence — charts built to the strictest forum standard travel between the Paris court, the German courts and the UPC without a rebuild

Strasbourg’s docket: pharma, chemistry and biotech

Strasbourg’s patent docket is written by its regional economy, and few French cities carry a heavier concentration of chemistry and life sciences. The Alsace pharmaceutical sector is anchored by major manufacturing on the city’s doorstep — Eli Lilly’s Fegersheim site, one of the group’s largest plants worldwide and a global centre for injectable and insulin-pen production, has drawn nine-figure investment to add capacity for new diabetes and metabolic therapies. Pharmaceutical patents generate the hardest infringement questions: formulation, process and device claims, plus supplementary protection certificates (SPCs) that extend protection on approved medicines, all of which must be proven from batch records, analytical data and regulatory filings — exactly the material a saisie-contrefaçon is designed to secure.

The second pillar is fundamental and fine chemistry. The University of Strasbourg is a European powerhouse in the field, home to Nobel laureates in chemistry — Jean-Marie Lehn (supramolecular chemistry) and Jean-Pierre Sauvage among them — and to institutes such as ISIS and the trinational biotechnology school ESBS. That research base feeds a dense cluster of chemistry, diagnostics, medical-technology and green-chemistry ventures across the Grand Est. Their disputes turn on catalyst, polymer, formulation and analytical-method claims, and on molecular-recognition and delivery technologies that have to be reverse-engineered from the accused product.

• Pharmaceuticals — formulation, process, device and SPC claims from the Alsace pharma base around Eli Lilly’s Fegersheim site, proven from batch, analytical and regulatory records
• Fine & fundamental chemistry — catalyst, polymer, formulation and analytical-method claims mapped from reverse chemistry and process parameters
• Biotech & diagnostics — molecular-recognition, delivery and diagnostic technologies rooted in the University of Strasbourg and BioValley research base
• Medtech & green chemistry — device and sustainable-process claims from the Grand Est innovation cluster, proven from deployed hardware and process data

Building claim charts and evidence-of-use for a French or UPC forum

The specialised Paris bench, the seizing expert on a saisie, and the UPC’s technically qualified panels all expect a disciplined evidentiary file — a chart that can be independently verified rather than merely argued. We start from claim construction, working through the claims, the specification and the prosecution history, then map each limitation against the real accused product and process, both literally and, where appropriate, under the doctrine of equivalents as applied in France.

• Element-by-element claim charts tying every limitation to a documented, dated piece of evidence a seizing expert can re-run
• Pharmaceutical evidence-of-use from formulation and process analysis, analytical data, batch records and SPC scope
• Chemistry evidence-of-use from reverse chemistry, catalyst and polymer analysis and process parameters
• Biotech and diagnostics evidence-of-use from teardown, assay analysis and molecular characterisation
• Non-infringement and design-around positions for an accused party, anchored to the specification and the file wrapper
• A coordinated invalidity file, because a nullity counterclaim runs alongside the infringement action in Paris, at INPI and at the UPC

The deliverable is scoped to the forum. A national action before the Paris Judicial Court, a French saisie-contrefaçon application, or a UPC infringement or revocation action each demands a slightly different package. What never changes is the core: a claim chart an independent expert and a specialist judge can adopt, built on evidence rather than conclusions and drafted to survive scrutiny in Paris, in Germany and at the UPC alike.

How PerspireIP scopes a Strasbourg infringement-analysis engagement

Every engagement follows the same path. We fix the correct claim construction, map each element against the accused product, and assemble evidence-of-use in the form the technology demands — formulation, process and regulatory data for pharma, reverse chemistry for fine-chemical matters, assay and characterisation work for biotech, teardown and telemetry for medtech. Then we build the file the French process actually uses: material a saisie-contrefaçon can secure and a commissaire de justice and independent expert can verify.

• Claim construction and element-by-element charting against a French national patent, a validated European patent or a unitary patent
• Evidence-of-use assembly dated and documented for a saisie-contrefaçon, a Paris Judicial Court judge or a UPC panel
• Infringement and non-infringement positions built for either side, coordinated with any parallel nullity, INPI revocation or UPC counterclaim
• Deliverables scoped to the track — a Paris complaint, a saisie application, or a UPC statement of claim, with the opt-out question and any cross-border German action flagged early

We work alongside your French and international counsel as a specialist analysis partner, deliver to Paris Judicial Court and UPC deadlines, and keep every engagement confidential. Whether you are a pharmaceutical maker, a chemistry or biotech company, or a medtech firm enforcing a portfolio, an accused party clearing a path to market, or litigation counsel preparing a claim or a defence across the Upper Rhine, we scale to fit — a single claim chart, a multi-patent matter, or ongoing portfolio support. Send us the patent number and the accused product, and we will scope the work within one business day.

IP Landscape & Resources in Strasbourg

Key intellectual-property authorities and venues relevant to Strasbourg:

• INPI (Institut national de la propriété industrielle) — the French National Institute of Industrial Property, which grants French patents, administers supplementary protection certificates, and since April 2020 hears administrative revocation and opposition actions against French patents
• French Ministry of Justice (Ministère de la Justice) — the official portal of the French justice system; the Paris Judicial Court (tribunal judiciaire de Paris) holds exclusive national jurisdiction over patent infringement and validity actions, with appeal to the Paris Court of Appeal
• Unified Patent Court (UPC) — the pan-European court that hears infringement and revocation of non-opted-out European patents and unitary patents, live since 1 June 2023, with the seat of its Central Division in Paris and further sections in Milan and Munich
• European Patent Office (EPO) — the office that grants European patents which, once validated in France or granted unitary effect, are enforced before the Paris Judicial Court or the UPC

Request a Patent Infringement Analysis in Strasbourg

Explore related PerspireIP services: Patent Infringement Analysis · Prior Art Litigation Search · Patent Invalidation.

Frequently Asked Questions